Supporting Collaborative and Innovative Programs to Advance the Lysosomal Storage Disorder Community Worldwide
Sanofi Genzyme’s Patient Advocacy Team launched the Patient Advocacy Leadership (PAL) Awards program in 2011 to encourage bold new ideas and programs to support the LSD community worldwide. The PAL Awards program funds collaborations that support innovative projects in disease awareness and education, community mobilization, non-profit development and good governance activities, patient care, and support programs. As an independent voice in the lysosomal storage disease community, patient organizations play a vital role in providing leadership, resources and access to care and support for patients and their families around the world. Sanofi Genzyme believes supporting their work is critical to optimizing patient care and meeting the ever-growing needs of the LSD community. Overwhelmingly successful in its first five years, we launched the 6th annual PAL Awards program in spring 2016.
The PAL Awards program is open to non-profit patient organizations, professional associations, and academic institutions. Only proposals involving collaboration between two or more organizations will be considered. For example, an LSD patient organization in one region of the world may choose to partner with an allied organization in another country to support learning exchanges between patient groups. Or, a patient group may partner with a university or hospital to further medical education.
A total of $50,000 may be awarded through competitive grants funding new initiatives that support the LSD community. All eligible applicants may apply for a maximum grant of $25,000.
"The mission of any of the organizations out there is to help spread awareness and information about the various conditions, and by participating in the PAL that gives you another tool essentially to be able to accomplish that mission, and the [Genzyme] PAL Awards program gives you access to resources to be able to fulfill that vision and that mission."